| Biomarker ID | 1409 |
| PMID | 24740842 |
| Year | 2014 |
| Biomarker | MIR605 [SNP: rs2043556: GG vs. AA/AG] |
| Biomarker Basis | Mutation Based |
| Biomolecule | Mutation |
| Source | Blood |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: Univariate: Cohort 1: [1.97 (95% CI: 1.14–3.40)]; Cohort 1+2: [1.70 (95% CI: 1.07–2.71)]HR: Multivariate: Cohort 1: [2.55 (95% CI: 1.34–4.84)]; Cohort 1+2: [1.96 (95% CI: 1.16–3.30)] |
| Effect on Pathways | Pathways include: phosphorylation; dendritic spine; actin filament organization; formation of primary germ layer; germ cell migration |
| Experiment | Biochemical recurrence Vs No Biochemical Recurrence |
| Type of Biomarker | Prognostic |
| Cohort | two independent cohorts composed of 320 Asian and 526 Caucasian men with pathologically organ-confined prostate cancer were selected |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | Univariate: Cohort 1: p= 0.02 Cohort 1+2: p=0.03;Multivariate: Cohort 1:p = 0.004 Cohort 1+2: p=0.01 |
| Method Used | MALDI-TOF |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |